Ultragenyx Pharmaceutical Inc RARE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ultragenyx to Participate in Investor Conferences in September
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
-
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
-
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $54.43
- Day Range
- $53.75–56.22
- 52-Week Range
- $31.52–60.37
- Bid/Ask
- $55.46 / $56.50
- Market Cap
- $5.12 Bil
- Volume/Avg
- 526,763 / 736,329
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.15
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,276
- Website
- https://www.ultragenyx.com
Comparables
Valuation
|
Metric
|
RARE
|
AVIR
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 11.60 | 0.61 | 1.74 |
Price/Sales | 9.15 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RARE
AVIR
PLRX
Financial Strength
|
Metric
|
RARE
|
AVIR
|
PLRX
|
|---|---|---|---|
Quick Ratio | 3.19 | 18.87 | 14.21 |
Current Ratio | 3.54 | 19.02 | 14.47 |
Interest Coverage | −8.24 | — | −106.49 |
Quick Ratio
RARE
AVIR
PLRX
Profitability
|
Metric
|
RARE
|
AVIR
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −31.64% | −23.62% | −27.65% |
Return on Equity (Normalized) | −218.50% | −25.11% | −31.11% |
Return on Invested Capital (Normalized) | −168.31% | −29.21% | −33.69% |
Return on Assets
RARE
AVIR
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kdknvcmsm | Yshz | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lzxkmyz | Tklpjs | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Yqqyyzzx | Kgvjdgy | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gjyfxxbk | Jxlkwm | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Kfvlnqqp | Xbht | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Vgqhvrfk | Ldlw | $28.1 Bil | |||
| Moderna Inc
MRNA
| Cswvsgm | Wylp | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Dmpbxsp | Qmx | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Prqhpdkp | Dqmtxp | $13.4 Bil | |||
| Incyte Corp
INCY
| Djsgdxqyn | Dbjfw | $12.7 Bil |
United States